Bristol Myers Squibb (BMS) has chosen Texas as the home to its new $2.3bn manufacturing facility – marking another significant investment into the state as the Trump administration's onshoring push continues.
The 600,000ft² site, located at Generation Park in the city of Houston, will be used to manufacture a wide range of BMS' next-generation pipeline and portfolio medicines. This includes biologics, small molecules and antibody-drug conjugates (ADC), and the facility's modular design will allow BMS to reconfigure when necessary.
BMS' new site will have the capacity to deal with the manufacture of both drug products and finished goods in the late development and commercial stages, providing flexibility to meet the company's needs in the future.
By building this digitally enabled facility, BMS will create nearly 500 skilled jobs, as well as around 2,000 construction and indirect roles during its erection.
This $2.3bn investment falls under the New Jersey-based pharma giant's $40bn commitment to bolstering its American business activity, with specific focus on enhancing its manufacturing and R&D footprint in the country.
It comes as the Trump administration continues to apply pressure on the pharma industry by looming the threat of tariffs in a bid to encourage the growth of manufacturing on US soil.
BMS makes its first in-house manufacturing foray into the state of Texas as global players increasingly recognise the state as a new hub for biopharma R&D and manufacturing.
According to Texas Governor Greg Abbott, this is largely due to "lower operating costs and easy access to markets across the US and the world", as well as the state's skilled present and future workforce.
BMS' CEO, Christopher Boerner, echoed this sentiment, noting that Houston and the state of Texas "offer the talent, infrastructure and partnership" needed to deliver the next generation of medicines.
This $2.3bn investment will expand BMS' connections to the state, as the company already works with a contract manufacturer clinical and commercial production company based in Texas.
BMS is not the only one eyeing Texas as a spot for new operations, as fellow pharma titan Eli Lilly pledged $6.5bn to build a production facility for its oral weight loss drug, Foundayo (orforglipron) in the state back in September 2025.
In a previous conversation with Pharmaceutical Technology, American biopharma players noted that states like Virginia and North Carolina represent rising stars as hubs for US biopharma activity. However, data from GlobalData's Pharmaceutical Intelligence Center reveals that Texas is the fifth most popular state for biotechs to house their operations.
GlobalData is the parent company of Pharmaceutical Technology.
"BMS banks on Texas for $2.3bn multi-modal manufacturing facility" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.